By blocking the activity of IL-4/IL-13 receptors, dupilumab may potentially lead to parasitic infections for users because both cytokines contribute to the elimination of parasites through increased mucus production and eosinophilic mucosal inflammation in the gut (35, 49–52). The gene discussed is IL4; the disease is parasitic infectious disease.